Answers are grounded in this paper and cite their sources.
OBJECTIVE: To investigate the value of Expanded Disability Status Scale (EDSS) worsening sustained for at least 6 months and other parameters as predictors for disability status. DESIGN: Retrospective analysis of the Multiple Sclerosis Collaborative Research Group study data. SETTING: The intramuscular interferon beta-1a pivotal trial was a double-blind, placebo-controlled phase 3 study. PARTICIPANTS: Patients with relapsing-remitting multiple sclerosis who received at least 2 years of treatment and completed an EDSS evaluation 8 years postrandomization. INTERVENTION: Thirty micrograms of intramuscular interferon beta-1a or placebo once weekly during the 2-year clinical trial. MAIN OUTCOME MEASURES: Positive predictive values for 6-month sustained progression during 2 years were calculated to determine the ability to predict disability status at 8 years. A multivariate logistic regression model was used to assess the relationship between predictors and EDSS milestones at follow-up. RESULTS: Forty-five patients had sustained 6-month EDSS progression during the clinical trial and 115 did not. Progression during the trial was the strongest predictor of reaching EDSS milestones at the follow-up visit, 8 years after randomization. Other independent predictors were treatment arm assignment and baseline EDSS score. CONCLUSION: In this phase 3 clinical trial of intramuscular interferon beta-1a, compared with effects of treatment, baseline EDSS score, and number of relapses during the study, worsening of 1 point or more on EDSS from baseline lasting 6 months was the strongest predictor of clinically significant disability 8 years after randomization into the clinical trial.
No takes yet. Share an insight, caveat, or question.
Rudick et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: